QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Everly, M. J Articles by Trofe, J. Search for Related Content PubMed PubMed Citation Articles by Everly, M. J Articles by Trofe, J.

TRANSPLANTATION

Posttransplant Lymphoproliferative Disorder

Transplant Pharmacy Resident, University of Cincinnati, Cincinnati, OH

Roy D Bloom, MD

Associate Professor of Medicine, School of Medicine, University of Pennsylvania, Philadelphia, PA

Donald E Tsai, MD PhD

Assistant Professor of Medicine, School of Medicine, University of Pennsylvania

Jennifer Trofe, PharmD BCPS

Clinical Transplant Pharmacist, Hospital of the University of Pennsylvania, Philadelphia

Reprints: Dr. Everly, University of Cincinnati, 231 Albert Sabin Way, ML 558, Cincinnati, OH 45267, fax 513/584-4455, matthew_everly{at}yahoo.com

OBJECTIVE: To define and discuss the pathogenesis, clinical presentation, diagnosis, risk factors, and current preventive and treatment strategies of posttransplant lymphoproliferative disorder (PTLD).

DATA SOURCES: MEDLINE was searched for articles published from January 1966 to July 2007. Search terms used include posttransplant lymphoproliferative disease, posttransplant malignancy, antiviral agents, interferon-alfa, rituximab, immunosuppression, chemotherapy, radiation, and surgery. Additional articles were identified by a hand search of references.

STUDY SELECTION AND DATA EXTRACTION: Studies in English of pediatric and adult solid organ transplantation populations published were selected and analyzed. Data from these studies and information from review articles were included in this review.

DATA SYNTHESIS: PTLD occurs in 1-20% of organ recipients following solid organ transplantation. PTLD risk factors include recipient pretransplant Epstein-Barr virus (EBV) negative serostatus, type of transplant, intensity of immunosuppression, and age. The PTLD presentation is variable. Some patients present asymptomatically; in others, early symptoms can be nonspecific. To prevent PTLD, minimizing immunosuppression burden and using antiviral agents active against EBV are useful strategies. PTLD treatment may require reduction of immunosuppression, radiation, surgical excision, monoclonal antibodies, interferon-alfa, and chemotherapy.

CONCLUSIONS: Screening for patients at risk and balancing the intensity of immunosuppressive regimens against the risk of rejection can substantially reduce the risk of developing PTLD. If PTLD occurs, an individualized treatment plan including decreased immunosuppression and other agents should be chosen based on the severity and extent of disease.

Key Words: immunosuppression, lymphoproliferation, posttransplant lymphoproliferative disorder

Published Online, October 16, 2007. www.theannals.com, DOI 10.1345/aph.1G706

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-07-026-H01

This article has been cited by other articles:

				S. A. Hunt and F. Haddad The Changing Face of Heart Transplantation J. Am. Coll. Cardiol., August 19, 2008; 52(8): 587 - 598. [Abstract] [Full Text] [PDF]